Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
25.57
+0.84 (3.40%)
At close: Jun 26, 2026, 4:00 PM EDT
25.34
-0.23 (-0.90%)
After-hours: Jun 26, 2026, 7:07 PM EDT
Denali Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
507
Market Cap
4.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 330.53M | 222.07M | 204.74% |
| Dec 31, 2022 | 108.46M | 59.80M | 122.90% |
| Dec 31, 2021 | 48.66M | -287.00M | -85.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.10B |
| Telix Pharmaceuticals | 803.79M |
| Catalyst Pharmaceuticals | 596.96M |
| Arcutis Biotherapeutics | 415.62M |
| Arcus Biosciences | 236.00M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Crinetics Pharmaceuticals | 18.07M |
DNLI News
- 8 days ago - Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV - TheFly
- 8 days ago - Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million - GlobeNewsWire
- 17 days ago - Denali Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 22 days ago - Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Denali Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley - TheFly
- 5 weeks ago - Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank - TheFly
- 5 weeks ago - Denali Therapeutics trading resumes - TheFly